Biogen Says FDA Approves New Avonex Syringe

Biogen ( BGEN) said the Food and Drug Administration has approved a new prefilled syringe for Avonex, the company's treatment for people with multiple sclerosis.

Biogen expects the prefilled syringe to be available in August and replace the currently marketed form of Avonex.

As with the current form of Avonex, the new formulation will be indicated to slow the progression of disabilities and reduce the frequency of relapses in MS patients. Avonex is administered once a week by intramuscular injection.

Shares of Biogen closed Wednesday at $42.37 in Nasdaq trading.

More from Stocks

Danica Patrick's Final Race at 2018 Indianapolis 500: What She Thinks About Cars

Danica Patrick's Final Race at 2018 Indianapolis 500: What She Thinks About Cars

Why The FANG Stocks' Dominance May Not Be So Bad For The Market

Why The FANG Stocks' Dominance May Not Be So Bad For The Market

At End of May, Investors Signalling They May Stay Away

At End of May, Investors Signalling They May Stay Away

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever